Adagene Inc.: Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates

Adagene (Nasdaq: ADAG) reported six months ended June 30, 2026 results and clinical updates on muzastotug (ADG126). Cash and equivalents were $127.9 million, extending runway into late 2028. Phase 1b/2 data in MSS CRC with pembrolizumab showed ORR 13% to 31% and median PFS 4.8 to 6.7 months, with Phase 2 results expected in 1H 2027.

Original reporting
Published Aug 12, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 12:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$ADAG
Bullish
medium confidence
Mentioned
$ADAG
Relevance
7/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$ADAGBullishMed
01

Why it matters

The company’s update combines (1) interim efficacy and safety detail by muzastotug dose schedule, (2) trial progression with a randomized Phase 2 readout targeted for 1H 2027, and (3) a cash runway extension into late 2028 following an April 2026 public offering.

02

Market read

Traders may reprice ADAG’s probability-weighted clinical success and financing risk based on the reported ORR/PFS by dose, the randomized Phase 2 timeline, and the stated cash runway into late 2028.

03

What to watch

The article emphasizes safety and ORR/PFS, but does not provide statistical significance, durability beyond medians, or full adverse-event detail across all cohorts, which can temper enthusiasm.

Relevance 7/10Novelty 6/10Timing: today’s pre-market/early session biotech catalyst from new interim clinical and cash runway details

Background

Adagene is a clinical-stage biotech developing muzastotug (ADG126), a masked anti-CTLA-4 SAFEbody, across MSS CRC and HCC in combination with PD-1 and other agents.

Company-level read

Ticker impact

$ADAGBullishMedium confidence
Context

Adagene reported six-month 2026 results and detailed muzastotug Phase 1b/2 efficacy, including ORR/PFS by dose and a randomized Phase 2 readout expected in 1H 2027.

Expected impact

Near-term sentiment likely positive on the combination of new clinical efficacy detail and runway extension, with volatility around the 1H 2027 Phase 2 readout.

Evidence & confidence

The article provides multiple concrete efficacy endpoints by dose regimen, ongoing trial timelines, and a stated cash runway extension from an April 2026 offering, all of which can move biotech risk perception.

Market effects

Reinforces investor appetite for next-gen CTLA-4 approaches and combination immunotherapy backbones in MSS CRC and HCC.

Limited direct regional spillover; primarily US-listed biotech sentiment.

Potential read-through to global oncology trial design and partnership activity, including collaboration with Sanofi and use of pembrolizumab/IO backbones.

Counterpoint

Interim Phase 1b/2 results are based on small cohorts and multiple dose schedules, so the market may discount the magnitude until randomized Phase 2 confirms dose regimen selection.

Key entities

  • Adagene Inc.

    Nasdaq-listed clinical-stage biotech reporting six-month 2026 financial results and muzastotug clinical updates.

  • muzastotug (ADG126)

    Masked anti-CTLA-4 SAFEbody being tested in MSS CRC and HCC combinations.

  • pembrolizumab (KEYTRUDA)

    Anti-PD-1 agent used in combination regimens described in the Phase 1b/2 and randomized Phase 2 designs.

  • Sanofi

    Clinical collaboration partner referenced for a global Phase 1/2 basket trial combining muzastotug with an investigational IO agent.

  • Merck (MSD outside US/Canada)

    Referenced as the source of the anti-PD-1 therapy used with muzastotug in MSS CRC.

Related articles

$ADAGLowAI 8/10

Adagene completes enrollment in phase 2 trial of muzastotug

Adagene Inc. (ADAG) completed enrollment in a Phase 2 trial of muzastotug, an anti-CTLA-4 antibody therapy, combined with Merck’s KEYTRUDA for late-line colorectal cancer. The trial enrolled 60 patients, with results expected in early 2027. The FDA confirmed Phase 3 trial design elements, and Sanofi invested in the trial. Muzastotug has FDA Fast Track designation.

$VNRXMed

VolitionRx reports clinical progress across diagnostic platform

VolitionRx (VNRX) reported progress in its Nu.Q diagnostic platform, with high sensitivity and specificity in detecting cancers. Its Nu.Q NETs test is part of a €6.3M French program. The company saw a 134% revenue increase, reduced operating losses, and is in licensing discussions. It also expanded a supply agreement with Fujifilm Vet Systems for a feline cancer test.